In comparison, NSCLC patients without BM showed 60 harboring wild‐type EGFR and mutant KRAS, 30 wild‐type ALK and 30 mutant ALK, ensuring similarity between patients from the two groups. This evidence concerns the gene KRAS and non-small cell lung carcinoma.